NCT00970229

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Institute for Neurodegenerative Disorders · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The underlying goal of this study is to assess \[123I\]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.

Detailed description

* To assess the dynamic uptake and washout of \[123I\]MNI-420 in brain using single photon emission computed tomography (SPECT) in Parkinson's disease (PD), Huntington's disease (HD), and similarly aged healthy subjects as a potential imaging biomarker of adenosine receptor type A2a (A2aR) in brain * To acquire initial safety data following injection of \[123I\]MNI-420

Conditions

• Parkinson Disease
• Huntington Disease

Interventions

Type	Name	Description
DRUG	[123I]MNI-420	Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.

Timeline

• Start date: 2009-07-01
• Primary completion: 2015-04-01
• Completion: 2015-05-01
• First posted: 2009-09-02
• Last updated: 2017-01-06

Locations

1 site across 1 country: United States